Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Significance: The cause of polycystic ovary syndrome (PCOS) is unknown, but androgen excess is a key feature. We combined a hyperandrogenized PCOS mouse model with global and tissue- and cell-specific androgen-resistant mouse lines to uncover the sites of androgen action that initiate PCOS. We demonstrate that direct androgen actions, particularly in neurons but less so in granulosa cells, are required for the development of key reproductive and metabolic PCOS features. These data highlight the previously overlooked importance of extraovarian neuroendocrine androgen action in the origins of PCOS. Targeting androgen-driven mechanisms may represent new options for developing a mechanism-based treatment of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“P ovary syndrome (PCOS) is the most frequent endocrine disorder of young women, with a prevalence of 6 to 15% (1), and accounts for more than 75% of anovulatory infertility (2).”
BackgroundDumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020 · cited 6×
“Walters KA, Handelsman DJ (2016) Androgen receptor splice variants and polycystic ovary syndrome: Cause or effect? Asian J Androl 18(3):442–443.”
BackgroundInfluentialSolon-Biet, S. M., McMahon, A. C., Ballard, J. W. O., Ruohonen, K., Wu, L. E., Cogger, V. C., Warren, A., Huang, X., Pichaud, N., Melvin, R. G., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.009 · Cited by 904 · cited 1×
“system (MC4000; Hatteras Instruments), as previously described (53).”
MethodTaylor, A. E., McCourt, B., Martin, K. A., Anderson, E. J., Adams, J. M., Schoenfeld, D., & Hall, J. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4105 · Cited by 494 · cited 1×
“Although species differences occur between humans and rodents in the site of action of positive estradiol feedback required to trigger the ovulatory LH surge (33), it is clear that alterations in GnRH pulse generation are present in women with PCOS (34).”
BackgroundEfficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain
Hayashi, S., Lewis, P., Pevny, L., & McMahon, A. P. (2002) · Mechanisms of Development · doi:10.1016/s0925-4773(03)00099-6 · Cited by 491
A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome
Mannerås, L., Cajander, S., Holmäng, A., Seleskovic, Z., Lystig, T., Lönn, M., & Stener-Victorin, E. (2007) · Endocrinology · doi:10.1210/en.2007-0168 · Cited by 483 · cited 2×
“Ovarian weight is increased in human PCOS but decreased in this rodent PCOS model (3, 28).”
BackgroundHayes, M. G., Urbanek, M., Ehrmann, D. A., Armstrong, L. L., Lee, J. Y., Sisk, R., Karaderi, T., Barber, T. M., McCarthy, M. I., Franks, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8502 · Cited by 478
Day, F. R., Hinds, D. A., Tung, J. Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjonnes, A., Broer, L., Dunger, D. B., Halldorsson, B. V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9464 · Cited by 459
Mannerås-Holm, L., Leonhardt, H., Kullberg, J., Jennische, E., Odén, A., Holm, G., Hellström, M., Lönn, L., Olivecrona, G., Stener-Victorin, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1290 · Cited by 369 · cited 1×
“Adiponectin, postulated to be a beneficial adipokine due to its insulin-sensitizing property and antiatherogenic action (40), is reduced in women with PCOS (41).”
BackgroundCaldwell, A. S. L., Middleton, L. J., Jimenez, M., Desai, R., McMahon, A. C., Allan, C. M., Handelsman, D. J., & Walters, K. A. (2014) · Endocrinology · doi:10.1210/en.2014-1196 · Cited by 342 · cited 8×
“To quantify antral follicle populations and assess follicular health, sections were examined using an Olympus light microscope with Stereo Investigator software (MBF Bioscience), as previously described (21).”
MethodResultInfluentialSelf-citationRodent Models for Human Polycystic Ovary Syndrome1
Walters, K. A., Allan, C. M., & Handelsman, D. J. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.111.097808 · Cited by 313
Self-citationSullivan, S. D., & Moenter, S. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308058101 · Cited by 308 · cited 1×
“Treatment with the AR antagonist flutamide is reported to restore ovulation in some women with PCOS (15) and rescue acyclicity (16) and anxiety-like behavior (17) in PCOS mouse models.”
BackgroundA CamKIIα iCre BAC allows brain‐specific gene inactivation
Casanova, E., Fehsenfeld, S., Mantamadiotis, T., Lemberger, T., Greiner, E., Stewart, A. F., & Schütz, G. (2001) · genesis · doi:10.1002/gene.1078 · Cited by 292
Metabolic risk in PCOS: Phenotype and adiposity impact
Moran, L. J., Norman, R. J., & Teede, H. J. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.12.003 · Cited by 245 · cited 1×
“Obesity is very common among women with PCOS and in turn leads to more severe hyperandrogenism (5, 35).”
BackgroundSertoli and granulosa cell‐specific Cre recombinase activity in transgenic mice
Lécureuil, C., Fontaine, I., Crepieux, P., & Guillou, F. (2002) · genesis · doi:10.1002/gene.10100 · Cited by 241 · cited 1×
“Female GCARKO mice were generated by crossing ARflox mice (46) with AMH-Cre mice (49), as previously reported (23).”
MethodSheep models of polycystic ovary syndrome phenotype
Padmanabhan, V., & Veiga-Lopez, A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.005 · Cited by 225
Dumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222 · cited 1×
“Altered adipose structure has been reported in PCOS women (43) and is linked with androgen excess, as prenatally androgenized female monkeys display impaired adipogenesis (44).”
BackgroundMoore, A. M., Prescott, M., Marshall, C. J., Yip, S. H., & Campbell, R. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415038112 · Cited by 217 · cited 2×
“Current evidence from a mouse PCOS model points to a role for androgen excess in promoting impaired progesterone-sensitive gamma-aminobutyric acid (GABA)ergic input to GnRH neurons within the arcuate nucleus of the hypothalamus (32).”
BackgroundResultGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 1×
“Supportive clinical evidence comes from findings that obese PCOS women consuming a hypocaloric diet together with an androgen antagonist (flutamide) exhibited additional favorable decreases in visceral fat compared with diet alone (36, 37).”
BackgroundTaylor, A. E. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2248 · Cited by 211
Brown adipose tissue transplantation ameliorates polycystic ovary syndrome
Yuan, X., Hu, T., Zhao, H., Huang, Y., Ye, R., Lin, J., Zhang, C., Zhang, H., Wei, G., Zhou, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523236113 · Cited by 202
Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism
Brennan-Speranza, T. C., Henneicke, H., Gasparini, S. J., Blankenstein, K. I., Heinevetter, U., Cogger, V. C., Svistounov, D., Zhang, Y., Cooney, G. J., Buttgereit, F., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63377 · Cited by 187 · cited 1×
“visualize lipid deposition, as previously described (52), before histo-”
MethodReproductive and Metabolic Phenotype of a Mouse Model of PCOS
van Houten, E. L. A. F., Kramer, P., McLuskey, A., Karels, B., Themmen, A. P. N., & Visser, J. A. (2012) · Endocrinology · doi:10.1210/en.2011-1754 · Cited by 184 · cited 2×
“We hypothesize that androgens are central in the etiology of PCOS, so in the current study we combined an optimized PCOS mouse model (20, 21) with global and neuron- and granulosa cellspecific androgen receptor knockout (ARKO) mouse lines (22, 23) to identify the sites of androgen action (Fig.”
MethodRole of androgens in normal and pathological ovarian function
Walters, K. A. (2015) · Reproduction · doi:10.1530/rep-14-0517 · Cited by 166 · cited 1×
“Animal models have shown that systemic treatment with androgens induces PCOS-like clinical features (19); however, systemic treatments cannot elucidate the target tissue(s) of androgenic actions.”
BackgroundSelf-citationWalters, K. A., Allan, C. M., Jimenez, M., Lim, P. R., Davey, R. A., Zajac, J. D., Illingworth, P., & Handelsman, D. J. (2007) · Endocrinology · doi:10.1210/en.2007-0248 · Cited by 146 · cited 4×
“We hypothesize that androgens are central in the etiology of PCOS, so in the current study we combined an optimized PCOS mouse model (20, 21) with global and neuron- and granulosa cellspecific androgen receptor knockout (ARKO) mouse lines (22, 23) to identify the sites of androgen action (Fig.”
MethodInfluentialSelf-citationNotini, A. J., Davey, R. A., McManus, J. F., Bate, K. L., & Zajac, J. D. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01884 · Cited by 145 · cited 4×
“Proc Natl Acad Sci USA 112(46):14348–14353.”
MethodInfluentialAndrogens and polycystic ovary syndrome
Nisenblat, V., & Norman, R. J. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832afd4d · Cited by 125 · cited 4×
“Hyperandrogenism, the most consistent feature of PCOS (5), is implicated as a key mediator in the pathogenesis of PCOS.”
BackgroundInfluentialWalters, K. A., Middleton, L. J., Joseph, S. R., Hazra, R., Jimenez, M., Simanainen, U., Allan, C. M., & Handelsman, D. J. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.112.102012 · Cited by 125 · cited 3×
“Mice containing the Sox2-Cre gene or the AMH-Cre gene were detected using primers and PCR conditions as described (23, 48).”
MethodSelf-citationKar, S. (2012) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.106338 · Cited by 123 · cited 1×
“Interestingly, by contrast, the treatment of women with PCOS with estrogen blockage, either by antiestrogen (clomiphene citrate) or an aromatase inhibitor (letrozole) that increases FSH secretion, is rapidly effective at inducing ovulation (30).”
BackgroundNeuroendocrine Effects of Androgens in Adult Polycystic Ovary Syndrome and Female Puberty
Blank, S., McCartney, C., Helm, K., & Marshall, J. (2007) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-984741 · Cited by 116 · cited 1×
“Taken together with the recent GWAS findings that implicate alterations in gonadotropin secretion in the origins of PCOS (24–26), our findings support the previous hypothesis that hyperandrogenism may impair neuronal circuits in the brain, leading to a disruption in sex steroid feedback mechanisms and abnormal gonadot…”
ResultHu, M., Richard, J. E., Maliqueo, M., Kokosar, M., Fornes, R., Benrick, A., Jansson, T., Ohlsson, C., Wu, X., Skibicka, K. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507514112 · Cited by 115 · cited 1×
“Treatment with the AR antagonist flutamide is reported to restore ovulation in some women with PCOS (15) and rescue acyclicity (16) and anxiety-like behavior (17) in PCOS mouse models.”
BackgroundInfertility in Polycystic Ovary Syndrome: Focus on Low-Dose Gonadotropin Treatment
Gorry, A., White, D. M., & Franks, S. (2006) · Endocrine · doi:10.1385/endo:30:1:27 · Cited by 114
Alternative splicing of the androgen receptor in polycystic ovary syndrome
Wang, F., Pan, J., Liu, Y., Meng, Q., Lv, P., Qu, F., Ding, G.-L., Klausen, C., Leung, P. C. K., Chan, H. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418216112 · Cited by 113 · cited 1×
“Support for AR-mediated androgen actions influencing the progression of PCOS includes that variation in androgen sensitivity via the CAG triplet repeat length polymorphism of the AR (11) is associated with PCOS prevalence (12), and alternative splicing of the AR in granulosa cells is associated with aberrant follicle…”
BackgroundNonhuman primate models of polycystic ovary syndrome
Abbott, D. H., Nicol, L. E., Levine, J. E., Xu, N., Goodarzi, M. O., & Dumesic, D. A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.013 · Cited by 107 · cited 1×
“Proc Natl Acad Sci USA 113(10):2708–2713.”
Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome
Chen, X., Jia, X., Qiao, J., Guan, Y., & Kang, J. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0247 · Cited by 107 · cited 1×
“Adipocyte dysfunction is also linked to PCOS pathogenesis (38, 39).”
BackgroundAdipocyte biology in polycystic ovary syndrome
Barber, T. M., & Franks, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.010 · Cited by 104 · cited 1×
“Adipocyte dysfunction is also linked to PCOS pathogenesis (38, 39).”
BackgroundPlant, T. M. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.02.002 · Cited by 100
Walters, K. A., McTavish, K. J., Seneviratne, M. G., Jimenez, M., McMahon, A. C., Allan, C. M., Salamonsen, L. A., & Handelsman, D. J. (2009) · Endocrinology · doi:10.1210/en.2008-1750 · Cited by 99 · cited 1×
“Reciprocal paired ovarian transplants were performed between wild-type and ARKO females as well as between wild-type and wild-type females as surgical controls for the procedure, as previously described (51).”
MethodSelf-citationGambineri, A., Pagotto, U., Tschöp, M., Vicennati, V., Manicardi, E., Carcello, A., Cacciari, M., Iasio, R. D., & Pasquali, R. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03347020 · Cited by 94 · cited 1×
“Supportive clinical evidence comes from findings that obese PCOS women consuming a hypocaloric diet together with an androgen antagonist (flutamide) exhibited additional favorable decreases in visceral fat compared with diet alone (36, 37).”
BackgroundCaldwell, A. S. L., Eid, S., Kay, C. R., Jimenez, M., McMahon, A. C., Desai, R., Allan, C. M., Smith, J. T., Handelsman, D. J., & Walters, K. A. (2015) · Endocrinology · doi:10.1210/en.2014-1887 · Cited by 91 · cited 4×
“Moreover, we recently identified that loss of AR signaling protects female mice from induction of PCOS features by prenatal hyperandrogenism (18).”
BackgroundResultInfluentialSelf-citationRole of adiponectin and some other factors linking type 2 diabetes mellitus and obesity
Chakraborti, C. K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1296 · Cited by 81 · cited 1×
“Adiponectin, postulated to be a beneficial adipokine due to its insulin-sensitizing property and antiatherogenic action (40), is reduced in women with PCOS (41).”
BackgroundLength of the human androgen receptor glutamine tract determines androgen sensitivity in vivo
Simanainen, U., Brogley, M. A., Gao, Y., Jimenez, M., Harwood, D. T., Handelsman, D. J., & Robins, D. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.011 · Cited by 66 · cited 1×
“Support for AR-mediated androgen actions influencing the progression of PCOS includes that variation in androgen sensitivity via the CAG triplet repeat length polymorphism of the AR (11) is associated with PCOS prevalence (12), and alternative splicing of the AR in granulosa cells is associated with aberrant follicle…”
BackgroundSelf-citationOvulatory effects of flutamide in the polycystic ovary syndrome
Paradisi, R., Fabbri, R., Battaglia, C., & Venturoli, S. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.754876 · Cited by 65 · cited 1×
“These findings are in agreement with clinical evidence supporting a direct role for androgen actions in the development of dysfunctional menstrual cycling and ovulation in PCOS, as prolonged treatment with the AR antagonist flutamide is reported to restore menstrual-cycle regularity and ovulation in some women with PC…”
ResultANTIANDROGEN TREATMENT OF POLYCYSTIC OVARY SYNDROME
Rittmaster, R. S. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70077-3 · Cited by 61
Keller, E., Chazenbalk, G. D., Aguilera, P., Madrigal, V., Grogan, T., Elashoff, D., Dumesic, D. A., & Abbott, D. H. (2014) · Endocrinology · doi:10.1210/en.2014-1050 · Cited by 60 · cited 1×
“Altered adipose structure has been reported in PCOS women (43) and is linked with androgen excess, as prenatally androgenized female monkeys display impaired adipogenesis (44).”
BackgroundTian, Y., Zhao, H., Chen, H., Peng, Y., Cui, L., Du, Y., Wang, Z., Xu, J., & Chen, Z.-J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3776 · Cited by 60
Fagman, J. B., Wilhelmson, A. S., Motta, B. M., Pirazzi, C., Alexanderson, C., Gendt, K. D., Verhoeven, G., Holmäng, A. B., Anesten, F., Jansson, J., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-259234 · Cited by 58 · cited 1×
“fat mass and cholesterol levels induced by a high-fat diet can be alleviated in ovariectomized female mice treated with DHT (45) indicate that a balance in direct AR actions is required to maintain normal metabolic function.”
BackgroundCharacterizing the neuroendocrine and ovarian defects of androgen receptor-knockout female mice
Cheng, X. B., Jimenez, M., Desai, R., Middleton, L. J., Joseph, S. R., Ning, G., Allan, C. M., Smith, J. T., Handelsman, D. J., & Walters, K. A. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00263.2013 · Cited by 55 · cited 2×
“Mice containing the Sox2-Cre gene or the AMH-Cre gene were detected using primers and PCR conditions as described (23, 48).”
MethodSelf-citationShorakae, S., Boyle, J., & Teede, H. (2014) · Internal Medicine Journal · doi:10.1111/imj.12495 · Cited by 49 · cited 1×
“Associated nonreproductive abnormalities, such as obesity, metabolic syndrome, hyperinsulinemia, insulin resistance, hepatic steatosis, and dyslipidemia predispose affected women to heightened risk of cardiovascular disease and type 2 diabetes (3, 4).”
BackgroundPolycystic ovaries in female-to-male transsexuals.
Pache, T. D., & Fauser, B. C. J. M. (1993) · PubMed · Cited by 47
Pignatelli, D. (2013) · Frontiers of Hormone Research · doi:10.1159/000342179 · Cited by 44 · cited 1×
“Supportive evidence includes that androgen excess from endogenous [congenital adrenal hyperplasia (6)] or exogenous [female-to-male transsexuals (7)] sources can produce polycystic ovaries.”
BackgroundBăculescu, N. (2013) · PubMed Central · Cited by 39
Androgen receptor splice variants and polycystic ovary syndrome: cause or effect?
Walters, K., & Handelsman, D. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.161600 · Cited by 16 · cited 1×
“Support for AR-mediated androgen actions influencing the progression of PCOS includes that variation in androgen sensitivity via the CAG triplet repeat length polymorphism of the AR (11) is associated with PCOS prevalence (12), and alternative splicing of the AR in granulosa cells is associated with aberrant follicle…”
BackgroundSelf-citationKar, S. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.07.313 · Cited by 11
Cited by
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Tata, B., Mimouni, N. E. H., Barbotin, A.-L., Malone, S. A., Loyens, A., Pigny, P., Dewailly, D., Catteau-Jonard, S., Sundström-Poromaa, I., Piltonen, T. T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0035-5 · Cited by 434
Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome
Stener-Victorin, E., Padmanabhan, V., Walters, K. A., Campbell, R. E., Benrick, A., Giacobini, P., Dumesic, D. A., & Abbott, D. H. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa010 · Cited by 348
Self-citation
Metadata
- Authors
- Caldwell, A. S. L., Edwards, M. C., Desai, R., Jimenez, M., Gilchrist, R. B., Handelsman, D. J., & Walters, K. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2017-03-20
- Volume
- 114
- Issue
- 16
- Pages
- E3334-E3343
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2600823667
- Cited by
- 219
- References
- 54
- FWCI
- 21.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.